Terazosin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Benign Prostatic Hyperplasia

Drugs & Aging

Volumn 3, Issue 3, 1993, Pages 258-277

  Wilde, Michelle I ^a   Fitton, Andrew ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC ALPHA ANTAGONISTS; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; PRAZOSIN; TERAZOSINE;

ADULT; AGED; COMPARATIVE STUDY; HUMAN; MALE; PROSTATE HYPERTROPHY; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; COMPARATIVE STUDY; HUMAN; MALE; MIDDLE AGE; PRAZOSIN; PROSTATIC HYPERPLASIA;

EID: 0027603691     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199303030-00007     Document Type: Article

References (71)

1. Terazosin: a new alpha adrenoceptor blocking drug
2. Prostatism
3. The development of human benign prostatic hyperplasia with age
4. Benign prostatic hypertrophy: what will be the therapeutic strategy for the 1990s?
5. Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed
6. The use of alpha adrenergic blockers in benign prostatic obstruction
7. Clinical experience with (α-adrenoceptor antagonists in benign prostatic hypertrophy
8. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy
9. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation
10. Alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasia
11. Effect of terazosin on the symptoms of benign prostatic hypertrophy (BPH). Abstract
12. Terazosin: an effective once-daily monotherapy for the treatment of hypertension
13. Quality of life assessment from efficacy and safety trials of terazosin in benign prostatic hyperplasia patients (BPH). Abstract
14. Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy
15. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study
16. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomised, double-blind placebo-controlled clinical trial
17. Analysis of presenting symptoms in prostatism
18. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy
19. The effect of finasteride in men with benign prostatic hyperplasia
20. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia
21. Urodynamics in benign prostatic hyperplasia: a survey
22. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate
23. Comparison of the α-adrenoceptor characteristics in human and canine prostate
24. In vitro characterization of the α-adrenoceptors in human prostate
25. Alpha-adrenergic blocking activities of terazosin, prazosin and bunazosin on isolated urethra muscle of the rabbit
26. Epidemiology and natural history of benign prostatic hyperplasia
27. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate
28. Etiology and disease process of benign prostatic hyperplasia
29. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin
30. Future directions in the management of benign prostatic hyperplasia
31. Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding
32. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra
33. Pharmacology of terazosin
34. In vivo uroselectivity of alfuzorin compared to prazosin and terazosin. Abstract
35. Nonoperative management of benign prostatic hyperplasia
36. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia
37. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment benign prostatic hyperplasia
38. The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain
39. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia
40. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH
41. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial
42. Efficacy of terazosin as an antihypertensive agent
43. Efficacy of terazosin in patients with benign prostatic hyperplasia
44. Origin and evaluation of benign prostatic enlargement
45. Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin
46. The influence of food on the oral bioavailability of terazosin
47. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients
48. Comparison of testosterone, 5 α-dihydrotestosterone and 5 α-androstane-3 β-17 β-diol metabolises in human normal and hyperplastic prostates
49. Human benign prostatic hyperplasia: a stromal disease?
50. Steroid hormones, receptors and benign prostatic hyperplasia
51. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia
52. Comparative trials of terazosin with other antihypertensive agents
53. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin
54. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplastic
55. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia
56. 1 adrenergic receptors in canine lower genitourinary tissues: insight into development function
57. The flow rate nomogram: II. Clinical correlation
58. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events
59. Pharmacokinetics of terazosin
60. The clinical effects of a 5 α-reductase inhibitor, finasteride, on benign prostatic hyperplasia
61. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension
62. 2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra
63. 1-adrenergic receptor antagonism mediated by terazosin in humans
64. The pathogenesis of benign prostatic hyperplasia
65. 1 blocker, terazosin
66. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy